This study applies a novel algorithm to longitudinal amyloid positron emission tomography (PET) imaging to identify age-heterogeneous amyloid trajectory groups, estimate the age and duration (chronicity) of amyloid positivity, and investigate chronicity in relation to cognitive decline and tau burden.
longitudinal patterns where detectable pathologic A accrues first, 3, 4 perhaps 20 or more years before clinically detectable cognitive impairment. 5, 6 The 2018 Research Framework for AD 7 proposes that amyloid PET may be used to ascertain amyloid status (ie, amyloid positive or negative [A+/−]). This dichotomization is heuristically useful, and multiple studies have shown that A+ cognitively unimpaired individuals exhibit greater cognitive decline over time than individuals who are A−, [8] [9] [10] with greater cognitive decline for people who exhibit both elevated pathologic amyloid and tau. 11, 12 However, among individuals who are accumulating amyloid, there is considerable heterogeneity in the magnitude and onset of amyloid accumulation with respect to age. 6, 13, 14 A method for elucidating such heterogeneity in amyloid-accumulating cases may improve prediction models of the temporal biomarker cascade and cognitive decline.
As observed by Jack et al. in their seminal paper, 1 there is little known about inter-individual differences in middle-age A accumulation when individuals are transitioning from undetectable (A−) to detectable (A+) amounts of A . The theoretical sigmoidal model of A accumulation 1 suggests that individuals have relatively slow accumulation initially, followed by faster accumulation as the disease progresses. Several approaches have examined ways to empirically assess the trajectory of A biomarkers in AD. 6, 13, 15, 16 These approaches often attempt to align persons within a disease state to mitigate the biomarker heterogeneity with respect to age. A method that combines A magnitude and amyloid measurement age to estimate the age at biomarker onset (ie, A+) could be useful in such scenarios because it would allow realignment of the time axis to describe the duration, or chronicity, of A+ relative to that person's age at any given procedure. Group-based trajectory modeling (GBTM) is used to describe the developmental course(s) a phenomenon might follow over time, 17, 18 and it is well-suited for characterizing potential sub-distributions of PET measured A pathology accumulation patterns with respect to age. Modeling these sub-distributions in a sample containing amyloid convertors across the age spectrum may allow for more accurate estimation of the age at which persons become A+.
Using data from the Wisconsin Registry for Alzheimer's Prevention (WRAP) study we investigated the following aims. First, we used longitudinal Pittsburgh compound B (PiB) to identify and characterize A trajectory groups of non-demented healthy middle-aged participants. Second, we examined whether trajectory group membership could be reliably obtained from only one PiB scan. We next utilized this trajectory group information to estimate the age at A+ (ie, PiB positivity, [PiB(+)]) onset, and thereby, the chronicity of A+ (ie, time between estimated A+ onset and age at a given assessment). Third, we characterized mathematically the shape of the amyloid accumulation curve observed in this sample. Fourth, we investigated whether A+ chronicity was associated with cognitive decline and with tau tangles. Tau tangles were assessed using [ 18 F]MK-6240, a novel PET radioligand with a high affinity for neurofibrillary tangles and minimal off-target binding in the brain. 19, 20 
HIGHLIGHTS
• Group-based trajectory modeling identifies age-based amyloid trajectory groups.
• Longitudinal trained algorithm can estimate age and duration of amyloid positivity.
• Amyloid-positive duration accounts for age-based amyloid accumulation heterogeneity.
• Longer amyloid duration is associated with greater tau burden and cognitive decline.
• Individuals with younger age at amyloid onset are more likely to be apolipoprotein 4 carriers.
RESEARCH IN CONTEXT
Previous studies have indicated that Alzheimer's disease (AD) has an extended prodromal period of two or more decades wherein pathological amyloid (A ) and tau proteins are aggregating prior to overt symptomology. Understanding longitudinal accumulation trajectories of amyloid and tau biomarkers is an area of active research, which is confounded by heterogeneity in these trajectories with respect to age. This study demonstrates a novel approach to estimating the age at amyloid onset informed by longitudinal positron emission tomography (PET) imaging. The results indicate that this approach can estimate the age at amyloid positivity within individuals, and thereby, the chronicity of amyloidosis, operationalized as duration of amyloid exposure at a given procedure. Application of this method has suggested that amyloid chronicity explains considerable heterogeneity in age-related amyloid accumulation trajectories and is associated with longitudinal cognitive decline and PET measured entorhinal tau tangles. This approach may enable an intuitive way to investigate temporal sequences in AD.
METHODS

Sample
The sample included 257 WRAP participants who were cognitively unimpaired at baseline and completed at least one PiB PET scan as of June 2019 ( 23 Logical Memory II, 24 and digit symbol substitution. 25 
Neuroimaging
All participants underwent T1-weighted magnetic resonance imaging (MRI), and [ 11 C]PiB ([ 11 C]6-OH-BTA-1). 26 Amyloid burden was assessed as a global cortical average PiB distribution volume ratio (DVR) 27 and a threshold of DVR ≥1.2 28 to ascertain PiB(+); 198 19 Radioligand synthesis and PET and MRI acquisition, processing, and analysis methods have been described previously 20, 29 and in supplemental materials.
Statistical methods
Statistical analyses were conducted in SAS and R. Sample characteristics were compared across groups of interest (eg, PiB trajectory groups) using tests appropriate for the distribution of the data. Tests included chi-square, fisher's exact, analysis of variance (ANOVA) and
Kruskal-Wallis.
Aim 1
We used GBTM on the 171 participants with two to four PiB scans to identify PiB trajectory groups. GBTM is a special case of pattern mixture modeling in which individuals are classified into groups on the basis of longitudinal data. 17, 30, 31 Models are fit iteratively by adding and removing groups based on the Bayesian information criteria (BIC) fit statistics. 17, 30 We modeled trajectories using up to a cubic polynomial, selecting the best parameterization based on BIC fit and reasonableness of the results. For example, if two functions had similar BIC for a group, the model that was more biologically probable was selected (ie, accumulating groups were not allowed to estimate PiB DVR values less than that of the non-accumulating group).
Aim 2
Using the GBTM functions and Bayes theorem (Equation 1, Table 2) to estimate the probability of group membership in group "j" for each participant's most recent scan, two re-weightings of the Bayes probabilities were applied to up-weight the probability of group 1 or 2 for low global PiB DVR values in age ranges where the trajectory functions were parallel and close (additional details described in supplement). Trajectory group membership was assigned as the group with maximum probability. Agreement between GBTM and Bayes theorem-derived trajectory group assignments was examined using Kappa statistics. 32
Aim 3
After observing strong agreement between PiB trajectory group assignment methods, the Bayes theorem approach was applied to all 257 participants to ascertain the probability of group membership and group assignment based on their global PiB DVR at their most recent scan. A+ age was then estimated for each participant using a probability weighted average of the A+ ages of the trajectory groups ( Abbreviations: DVR, distribution volume ratio; GBTM, group-based trajectory modeling; PiB, Pittsburgh compound B. Equation 1 notes: Pr(Group J) = proportion assigned to each group via GBTM (for j = groups 1-4, respectively). Pr(Observed PiB|Group J) was obtained by getting the mean(SD) residual for all scans of people assigned to group J and using these values to convert residuals for group J to z-scores. We then used the normal distribution to obtain the probability of observing a residual as or more extreme than that one relative to Group J. Similarly, Pr(Observed PiB) was calculated as the probability of observing a global PiB DVR as or more extreme than the observed PiB. Post-Bayes theorem re-weightings for two conditions are described in supplemental materials. Equation 2 note: "Group 1 Age" is the estimated life expectancy given participant's sex and current age. 
Aim 4
We used linear mixed-effects (LME) models to examine whether amyloid chronicity at baseline PACC-3 modified longitudinal PACC-3 scores (random intercept and age-related slope; unstructured covariance; n = 254 after excluding one participant with multiple sclerosis and two missing PACC-3 scores). Fits of the base model (covariates of sex, Wide Range Achievement Test 3
[WRAT3], practice, age, and age 2 ) were compared with a model that included amyloid chronicity and its interaction with age and age 2 .
After observing better model fit (a sufficiently lower value of the corrected-Akaike information criteria [AICc] statistics 33 ) for the latter model and significant interactions, we depicted the effects of amyloid chronicity on cognitive trajectories by plotting age trajectories for amyloid chronicity values that represented mean chronicity at PACC-3 baseline in each of the four PiB trajectory groups.
In secondary analyses, we used logistic regression to examine whether concurrent amyloid chronicity and age were associated with increased risk of abnormal cognition at the most recent visit using three definitions of abnormal (progression to clinical impairment, abnormal relative to internal cross-sectional norms, and abnormal relative to longitudinal norms; see supplemental materials).
We used regression to compare age and amyloid chronicity at MK- 
RESULTS
Aim 1
In the subset used for GBTM (n = 171), mean(SD) age at first scan was 61. Table 2 ).
Group functions and observed data are shown in Figure 1A . indicated an intercept only model that was below the PiB(+) threshold. 
Aim 2
We observed strong agreement between PiB trajectory group assignment using GBTM (longitudinal scans) versus using trajectory group functions and Bayes theorem (only most recent scan in the GBTM set 
Aim 3
Using the Bayes theorem approach, we obtained group membership probabilities for all 257 participants, including 86 not included in GBTM modeling, which was used to assign PiB trajectory group membership (sample characteristics in Table 1 ). Equations 2 and 3 ( Table 2) were then used to estimate amyloid chronicity for all participants based on their last PiB scan.
The four trajectory groups did not differ in terms of baseline PACC-3 performance, WRAT3 reading, years of education, race, or sex, but did differ in amyloid chronicity at most recent scan, parental history of AD, and APOE4 carriage. Follow-up pairwise comparisons among trajectory groups showed more APOE4 carriage in each of the accumulating groups compared to group 1 and more parental history of AD in group 4 (the earliest accumulating group) compared to group 1.
Plots depicting PiB DVR versus chronicity and chronological age are shown in Figure 1 (1B shows longitudinal plots for the GBTM subset; Figure 1C and D are plotted cross-sectionally using most recent PiB).
Chronicity and most recent PiB DVR were highly correlated (Pearson r = 0.895), with a quadratic model indicating a good fit for chronicity predicting PiB DVR (R 2 = 0.945 for all 257 participants, R 2 = 0.931 including only groups 2-4; Table 2 Equations 8 and 9, respectively).
Using 
Entorhinal tau
One hundred ninety-eight participants (77%) also underwent MK-6240 PET scans (mean(SD) of 0.10(0.32) years between last PiB and MK-6240 scans; mean(SD) age at MK-6240 scan = 67.6(6.4)). Amyloid chronicity at the time of MK-6240 differed between all PiB trajectory groups in a stepwise manner (Table 1) (Figure 4 ;
ΔAICc chronicity-age models = −120.7). Including the trajectory group term and its interaction with chronicity in the model indicated that MK-6240 SUVR values were 1.1, 3, and 10.6 times higher for the amyloid-accumulating groups (ie, groups 2-4, respectively) compared to the non-accumulating group (ie, group 1; interaction P-value < 0.0001; ΔAICc chronicity polynomial-group*chronicity interaction model = −6.5).
Sensitivity analyses replacing chronicity with PiB(+/−) status indicated that PiB(+/−) status was also a significant predictor of MK-6240 entorhinal cortex SUVR, although it was a weaker predictor than chronicity (Figure 4 ; ΔAICc chronicity-PiB(+) models = −81.5).
Replacing amyloid chronicity with Global PiB DVR yielded models with a similar fit (ΔAICc chronicity-global PiB DVR models = −1.3).
DISCUSSION
This work demonstrates a novel application of GBTM and Bayes theorem to identify amyloid trajectory groups with respect to chronological age and to estimate the age of amyloid positivity within groups and individuals, and thereby, the time duration of exposure to pathologic A (ie, amyloid chronicity). This methodology was applied to investigate differences between trajectory groups and relationships between amyloid duration, chronological age, PET measured neurofibrillary tangles, and cognitive trajectories of initially cognitively unimpaired persons. Among the key findings was that the estimated duration of amyloid positivity (ie, amyloid chronicity) maintained information about dichotomous amyloid status while simultaneously preserving information about the severity of amyloidosis. In addition, this approach provided insights regarding the heterogeneity of amyloid accumulation trajectories with respect to age that become homogeneous when reordering the time-axis to reflect the estimated duration of amyloidosis.
A modeling and rates of accumulation
Previous studies have used several different approaches and cohorts to model amyloid trajectories with respect to age and amyloid biomarker levels. 1, 6, 15, 35, 36 These studies suggest that individuals in the AD continuum begin accumulating A at different ages, but experience similar rates of amyloid accumulation for a given level of amyloidosis. In agreement with these studies, the GBTM results suggest that there exist subgroups of amyloid accumulators that 
Chronology of A relative to tau and cognitive decline
Understanding the chronology of AD biomarkers and their prognostic value is important for contextualizing studies relating AD biomarkers to symptomology and other disease outcomes, and for clinical trial design. Previous studies have proposed different methods for obtaining metrics reflective of disease state. 1, 3, 15, [35] [36] [37] In contrast to those methods, the approach in this study uses fewer model parameters and less complex model functions. Furthermore, the relative timing between chronological events is not affected by the positivity thresh- impairment. These intuitive results may partly explain why some studies demonstrate a relationship between A+ status and cognition during the preclinical stage, whereas others do not. 8, [38] [39] [40] [41] Similar to relationships with cognition, models including chronicity to explain entorhinal tau tangles improved model fits compared to models with age alone or dichotomous amyloid status. Furthermore, these results suggested a time-lapsed relationship wherein tangles were detectable several years after the detection of pathologic A . In agreement with previous studies, these results support the hypotheses that the level of amyloid tracer binding is reflective of the cumulative process of amyloidosis and that markers of AD pathophysiology and cognition follow a temporal hierarchy. In addition, these results support previous findings that suggest that age is a risk factor for pathophysiology and cognitive decline in AD, but age itself is not a robust predictor of amyloidosis, entorhinal tangles, and thereby, AD state.
The major contribution of this "proof of concept" study is that the trajectory of amyloid accumulation, age at amyloid positivity, and its chronicity can be estimated and used to describe the disease course of amyloidosis. Study limitations include the following. WRAP is a volunteer cohort with over-sampling of participants with a parental history of AD; this results in higher AD-risk characteristics than in the general population. In addition, the sample is younger and more cognitively intact compared to other longitudinal studies of amyloid accumulation; thus, it is unlikely that our exact equations and parameters will generalize to other radiotracers and study samples. As such, replication of this method in different cohorts is needed to determine to what extent this approach is generalizable. If replicable, estimates of amyloid onset and chronicity, such as described here, should be examined in other research contexts to better understand the impact of treatments, preventative measures, and resilience factors during the preclinical phase of AD. Fund. These funding sources did not contribute to study design, analysis, interpretation, or writing of this work. We would like to thank all participants and their families, and the many study teams at the University of Wisconsin-Madison that make this work possible. 
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